US Bancorp DE Has $92,000 Stock Holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

US Bancorp DE lowered its stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) by 36.4% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 12,497 shares of the biotechnology company’s stock after selling 7,158 shares during the period. US Bancorp DE’s holdings in Iovance Biotherapeutics were worth $92,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the stock. SG Americas Securities LLC purchased a new stake in shares of Iovance Biotherapeutics during the fourth quarter worth $515,000. Jennison Associates LLC purchased a new stake in shares of Iovance Biotherapeutics during the 4th quarter worth about $493,000. Barclays PLC lifted its holdings in shares of Iovance Biotherapeutics by 118.8% during the 3rd quarter. Barclays PLC now owns 604,584 shares of the biotechnology company’s stock valued at $5,677,000 after buying an additional 328,284 shares during the last quarter. Principal Financial Group Inc. lifted its holdings in shares of Iovance Biotherapeutics by 59.0% during the 3rd quarter. Principal Financial Group Inc. now owns 4,033,184 shares of the biotechnology company’s stock valued at $37,872,000 after buying an additional 1,496,941 shares during the last quarter. Finally, Intech Investment Management LLC bought a new stake in shares of Iovance Biotherapeutics in the 3rd quarter valued at approximately $920,000. Institutional investors and hedge funds own 77.03% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on IOVA shares. Piper Sandler cut their price objective on shares of Iovance Biotherapeutics from $7.50 to $6.00 and set a “neutral” rating on the stock in a research report on Friday, February 28th. Truist Financial reduced their price objective on shares of Iovance Biotherapeutics from $25.00 to $15.00 and set a “buy” rating for the company in a research note on Monday, March 3rd. Chardan Capital reduced their price target on Iovance Biotherapeutics from $34.00 to $30.00 and set a “buy” rating for the company in a research report on Monday, March 3rd. HC Wainwright reiterated a “buy” rating and set a $32.00 price target on shares of Iovance Biotherapeutics in a research note on Friday, February 28th. Finally, Robert W. Baird cut their price objective on Iovance Biotherapeutics from $24.00 to $20.00 and set an “outperform” rating on the stock in a research note on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $20.25.

Iovance Biotherapeutics Stock Performance

Shares of IOVA stock opened at $3.74 on Tuesday. The firm has a fifty day moving average of $5.40 and a 200-day moving average of $7.96. The stock has a market cap of $1.23 billion, a price-to-earnings ratio of -2.51 and a beta of 0.93. Iovance Biotherapeutics, Inc. has a 52-week low of $3.48 and a 52-week high of $15.90.

Iovance Biotherapeutics (NASDAQ:IOVA) last announced its quarterly earnings results on Thursday, February 27th. The biotechnology company reported ($0.26) EPS for the quarter, hitting analysts’ consensus estimates of ($0.26). The firm had revenue of $73.69 million during the quarter, compared to analysts’ expectations of $72.17 million. Iovance Biotherapeutics had a negative net margin of 451.25% and a negative return on equity of 58.43%. On average, sell-side analysts predict that Iovance Biotherapeutics, Inc. will post -1.24 earnings per share for the current year.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.